This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schreiber, T. L. Articles by Margulis, A. Search for Related Content PubMed PubMed Citation Articles by Schreiber, T. L. Articles by Margulis, A.

Circulation, Vol 86, 1407-1414, Copyright © 1992 by American Heart Association

ARTICLES

Randomized trial of thrombolysis versus heparin in unstable angina

TL Schreiber, D Rizik, C White, GV Sharma, M Cowley, G Macina, PS Reddy, L Kantounis, GC Timmis and A Margulis
William Beaumont Hospital, Royal Oak, Mich. 48073-6769.

BACKGROUND. The clinical usefulness of intravenous thrombolytic therapy in unstable angina is currently unknown, despite the pathogenetic similarity of this entity to acute myocardial infarction, for which thrombolysis has enjoyed great success. To compare the clinical benefit of intravenous urokinase with that of conventional antithrombotic therapy in preventing the progression of unstable angina to new myocardial infarction, intractable angina, or death within the first 96 hours after hospitalization, 149 patients with unstable angina were randomized to one of two intravenous thrombolytic strategies. METHODS AND RESULTS. Forty-nine patients received 3 million units urokinase i.v. over 90 minutes plus intravenous heparin (group A); 47 patients received unblinded 3 million units urokinase i.v. plus 325 mg aspirin p.o. daily (group B); and 53 patients received placebo thrombolytic infusion plus full-dose heparin (group C). The primary end point of this trial was 96-hour clinical status. There were no significant differences in the baseline characteristics (age, sex, previous myocardial infarction, hypertension prevalence, diabetes, tobacco use, or previous revascularization) among the three groups. Despite an excess of minor untoward reactions for the urokinase groups (chills, 26.5% and 23.4% for groups A and B versus 0% for group C; p < 0.01), there was no significant difference with respect to major bleeds (two, none, and two for groups A, B, and C, respectively; p = NS). At 96 hours after presentation, no significant difference emerged in the incidence of new cardiac events: new myocardial infarctions developed in 10.2% of group A, 6.4% of group B, and 3.8% of group C (p = NS); intractable angina occurred in 6.1% of group A, 10.6% of group B, and 9.4% of group C (p = NS). There were no deaths. All three groups encountered a similar incidence of overall cardiac events: 16.3%, 17.0%, and 13.2% for groups A, B, and C, respectively (p = NS). Although trial enrollment was to extend to 600 patients, interim analysis led to early cessation of enrollment due to a negative trend in respect to outcome after thrombolysis. CONCLUSIONS. High-dose intravenous urokinase followed by either heparin or aspirin can be safely administered to a broad, unselected group of patients with unstable angina. However, this study suggests that no clinical advantage is conferred by urokinase, with either adjunctive antithrombotic therapy over standard heparin therapy alone, when given relatively late (mean, 8.7 hours) after admission for unstable angina. A possible detrimental effect cannot be excluded.

This article has been cited by other articles:

				M. E. Bertrand, M. L. Simoons, K. A.A. Fox, L. C. Wallentin, C. W. Hamm, E. McFadden, P. J. De Feyter, G. Specchia, and W. Ruzyllo Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur. Heart J., December 1, 2002; 23(23): 1809 - 1840. [Full Text] [PDF]

				G. N. Levine, M. N. Ali, and A. I. Schafer Antithrombotic Therapy in Patients With Acute Coronary Syndromes Arch Intern Med, April 9, 2001; 161(7): 937 - 948. [Abstract] [Full Text] [PDF]

				R. T. Schermuly, A. Gunther, M. Ermert, L. Ermert, H. A. Ghofrani, N. Weissmann, F. Grimminger, W. Seeger, and D. Walmrath Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation Am J Physiol Lung Cell Mol Physiol, April 1, 2001; 280(4): L792 - L800. [Abstract] [Full Text] [PDF]

				M.E Bertrand, M.L Simoons, K.A.A Fox, L.C Wallentin, C.W Hamm, E McFadden, P.J de Feyter, G Specchia, and W Ruzyllo Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology: Recommendations of the Task Force of the European Society of Cardiology Eur. Heart J., September 1, 2000; 21(17): 1406 - 1432. [PDF]

				P. A. McCullough, W. W. O'Neill, M. Graham, R. J. Stomel, F. Rogers, S. David, A. Farhat, R. Kazlauskaite, M. Al-Zagoum, and C. L. Grines A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy: Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial J. Am. Coll. Cardiol., September 1, 1998; 32(3): 596 - 605. [Abstract] [Full Text] [PDF]

				R. P. Giugliano, C. A. Camargo Jr, D. M. Lloyd-Jones, J. D. Zagrodsky, J. D. Alexis, K. A. Eagle, V. Fuster, and C. J. O'Donnell Elderly Patients Receive Less Aggressive Medical and Invasive Management of Unstable Angina: Potential Impact of Practice Guidelines Arch Intern Med, May 25, 1998; 158(10): 1113 - 1120. [Abstract] [Full Text] [PDF]

				UROKINASE VS. HEPARIN FOR UNSTABLE ANGINA Journal Watch (General), November 17, 1992; 1992(1117): 3 - 3. [Full Text]